{"commentary":{"count":15,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":7,"podcast":4,"x_thread":3,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05797168\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"FONTANA","nct_id":"NCT05797168","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fontana-nct05797168. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"FONTANA","arms":[{"description":"Torvu-sam Monotherapy","label":"Module 1: Torvu-sam Monotherapy","type":"EXPERIMENTAL"},{"description":"Torvu-sam + Saruparib","label":"Module 2: Torvu-sam + Saruparib","type":"EXPERIMENTAL"},{"description":"Torvu-sam + Bevacizumab","label":"Module 3: Torvu-sam + Bevacizumab","type":"EXPERIMENTAL"},{"description":"Torvu-sam + Carboplatin +/- Bevacizumab","label":"Module 4: Torvu-sam + Carboplatin +/- Bevacizumab","type":"EXPERIMENTAL"},{"description":"Torvu-sam + Palacaparib +/- Bevacizumab","label":"Module 5: Torvu-sam + Palacaparib +/- Bevacizumab","type":"EXPERIMENTAL"},{"description":"Torvu-sam + Pembrolizumab +/- Palacaparib","label":"Module 6: Torvu-sam + Pembrolizumab +/- Palacaparib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-08-04","type":"ESTIMATED"},"conditions":["Ovarian Cancer","Lung Adenocarcinoma","Endometrial Cancer","Lung Squamous Cell Carcinoma"],"enrollment":{"count":622,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Torvutatug samrotecan","type":"DRUG"},{"name":"Saruparib","type":"DRUG"},{"name":"Bevacizumab","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Palacaparib","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"}],"last_update":"2026-10-05","lead_sponsor":"AstraZeneca","official_title":"A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-08-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants with adverse events/serious adverse events","timeFrame":"From time of Informed Consent to 30 days post last dose."},{"measure":"The number of participants with dose limiting toxicity(DLT), as defined in the protocol","timeFrame":"From the first dose of torvu-sam on Cycle 1 Day 1 up to and including the planned end of Cycle 1 (At the end of 21 days)"}],"references":[],"start_date":{"date":"2023-06-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05797168"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fontana-nct05797168"}